Zhongzheng Intelligent Finance News: On November 30th evening, Ascletis Pharma Inc.-B (01672) announced that the company has selected its first oral GLP-1R/GIPR/GCGR triple-target agonist peptide ASC37 for clinical development. It is expected that the company will submit an IND application for the oral tablet of ASC37 to the US Food and Drug Administration (FDA) in the second quarter of 2026. In the head-to-head study in non-human primates, the average absolute oral bioavailability of the ASC37 oral tablet reached 4.2%, which was approximately 9 times, 30 times, and 60 times that of semaglutide, teprotide, and retatrutide using the oral SNAC formulation technology, respectively.

The announcement states that the study shows that the drug exposure level of ASC37 oral tablets (measured by the area under the drug-time curve) is approximately 57 times that of retatrutide. The average apparent half-life of the oral tablet in non-human primates in the study was approximately 56 hours, supporting once-daily or less frequent oral administration. In vitro experiments indicated that ASC37 was approximately 5 times, 4 times, and 4 times more potent than retatrutide in terms of agonistic activity towards GLP-1R, GIPR, and GCGR, respectively.

ASC37 was developed by Ascend using its proprietary oral peptide delivery enhancement technology (POTENT) and structure-based AI-assisted drug discovery technology (AISBDD). Dr. Wu Jinzi, the founder, chairman of the board and CEO of Ascend, stated that the selection of ASC37 once again demonstrates the company's strong R&D capabilities and showcases its determination to address the unmet needs in the field of obesity treatment.

The company will hold a telephone communication meeting (in Mandarin) at 10:00 a.m. on December 1, 2025. You can participate via Tencent Meeting or VooV Meeting.

https://finance.eastmoney.com/a/202511303578467216.html